This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Available Dosage Form & Package:
- 1 mg × Single-dose vial and 2 vials of 7 mL IV Solution Stabilizer
- 10 mg × Single-dose vial and 2 vials of 7 mL IV Solution Stabilizer
Shipping:
Cold chain shipping
Certain medicinal ingredients are sensitive to heat, light, and handling.
To maintain product quality, IMDELLTRA is shipped using a cold chain delivery system.
Specialized medical couriers use temperature-controlled boxes and vehicles to ensure the medicine remains stable and uncompromised throughout transit.
Because of these precautions, cold chain shipping can be slightly more expensive than regular delivery methods.
Disease Indications:
Lung Cancer (Extensive-Stage Small Cell Lung Cancer – ES-SCLC)
Manufacturer:
Amgen Inc. (United States)
IMDELLTRA (tarlatamab-dlle)
General Description:
Imdelltra (tarlatamab-dlle) is a prescription immunotherapy developed by Amgen Inc. (U.S.) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
It is a bispecific T-cell engager (BiTE®) designed to help the immune system target and destroy DLL3-expressing cancer cells. By connecting T-cells to tumor cells, Imdelltra supports the body’s natural ability to fight lung cancer more effectively.
Getting Imdelltra (tarlatamab-dlle) in India
Imdelltra (tarlatamab-dlle) received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2024 for the treatment of extensive-stage small cell lung cancer. It is also under review by the European Medicines Agency (EMA) and Health Canada.
At present, Imdelltra is not commercially available in India, but eligible patients can access it legally through the Named Patient Program (NPP) under their oncologist’s supervision.
MitoGENE assists Indian patients and healthcare providers in obtaining Imdelltra (tarlatamab-dlle) through a compliant import process. We manage all documentation, regulatory permissions, and international logistics to ensure safe and legal access to this innovative lung cancer treatment in India.
If you or your loved one may benefit from Imdelltra (tarlatamab-dlle), MitoGENE can help you access the medicine smoothly under your doctor’s guidance.
Medicine Approved by:
Health Canada (under review)
U.S. Food and Drug Administration (FDA)
European Medicines Agency (EMA) (under review)
If Imdelltra (tarlatamab-dlle) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
How to Access Imdelltra (tarlatamab-dlle) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
